Beyond <em>LKB1</em> Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment
LKB1 is frequently mutated in non-small cell lung cancer (NSCLC). LKB1-mutated NSCLCs often have a dismal prognosis and receive lower benefit from the currently available therapies. LKB1 acts as a cell emergency brake in low-energy conditions, by modulating the activity of crucial anabolic enzymes....
Main Authors: | Cristina Borzi, Giulia Galli, Monica Ganzinelli, Diego Signorelli, Claudio Vernieri, Marina Chiara Garassino, Gabriella Sozzi, Massimo Moro |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/13/11/385 |
Similar Items
-
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy
by: Gloriana Ndembe, et al.
Published: (2024-01-01) -
LKB1 suppression promotes cardiomyocyte regeneration via LKB1-AMPK-YAP axis
by: Shuang Qu, et al.
Published: (2022-09-01) -
Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies
by: Ichidai Tanaka, et al.
Published: (2023-08-01) -
Sensory neuron LKB1 mediates ovarian and reproductive function
by: Melissa E Lenert, et al.
Published: (2024-11-01) -
Insights into targeting LKB1 in tumorigenesis
by: Charles B. Trelford, et al.
Published: (2025-03-01)